SRZN
Price
$13.50
Change
+$0.55 (+4.25%)
Updated
Nov 19 closing price
Capitalization
115.71M
Intraday BUY SELL Signals
UPB
Price
$24.94
Change
-$0.62 (-2.43%)
Updated
Nov 19 closing price
Capitalization
1.35B
Intraday BUY SELL Signals
Interact to see
Advertisement

SRZN vs UPB

Header iconSRZN vs UPB Comparison
Open Charts SRZN vs UPBBanner chart's image
Surrozen
Price$13.50
Change+$0.55 (+4.25%)
Volume$38.68K
Capitalization115.71M
Upstream Bio
Price$24.94
Change-$0.62 (-2.43%)
Volume$422.24K
Capitalization1.35B
SRZN vs UPB Comparison Chart in %
SRZN
Daily Signal:
Gain/Loss:
UPB
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
SRZN vs. UPB commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SRZN is a Hold and UPB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (SRZN: $13.50 vs. UPB: $24.89)
Brand notoriety: SRZN and UPB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SRZN: 75% vs. UPB: 101%
Market capitalization -- SRZN: $115.71M vs. UPB: $1.35B
SRZN [@Biotechnology] is valued at $115.71M. UPB’s [@Biotechnology] market capitalization is $1.35B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SRZN’s FA Score shows that 1 FA rating(s) are green whileUPB’s FA Score has 0 green FA rating(s).

  • SRZN’s FA Score: 1 green, 4 red.
  • UPB’s FA Score: 0 green, 5 red.
According to our system of comparison, SRZN is a better buy in the long-term than UPB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SRZN’s TA Score shows that 6 TA indicator(s) are bullish while UPB’s TA Score has 3 bullish TA indicator(s).

  • SRZN’s TA Score: 6 bullish, 4 bearish.
  • UPB’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, SRZN is a better buy in the short-term than UPB.

Price Growth

SRZN (@Biotechnology) experienced а +4.33% price change this week, while UPB (@Biotechnology) price change was +4.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
UPB($1.35B) has a higher market cap than SRZN($116M). UPB YTD gains are higher at: 51.399 vs. SRZN (-5.923). SRZN has higher annual earnings (EBITDA): -24.83M vs. UPB (-121.42M). UPB has more cash in the bank: 394M vs. SRZN (90.4M). UPB has less debt than SRZN: UPB (1.56M) vs SRZN (7.51M). SRZN has higher revenues than UPB: SRZN (12.6M) vs UPB (2.72M).
SRZNUPBSRZN / UPB
Capitalization116M1.35B9%
EBITDA-24.83M-121.42M20%
Gain YTD-5.92351.399-12%
P/E RatioN/AN/A-
Revenue12.6M2.72M463%
Total Cash90.4M394M23%
Total Debt7.51M1.56M481%
TECHNICAL ANALYSIS
Technical Analysis
SRZNUPB
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
80%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
87%
MACD
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 4 days ago
89%
Declines
ODDS (%)
Bearish Trend 11 days ago
83%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
73%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
SRZN
Daily Signal:
Gain/Loss:
UPB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ECDIX18.89N/A
N/A
Eaton Vance Global Equity Income C
LCEVX19.20N/A
N/A
Invesco Diversified Dividend C
MGQIX17.09N/A
N/A
Morgan Stanley Inst Global Stars I
SWMCX14.16N/A
N/A
Schwab ® US Mid-Cap Index
DILYX15.79-0.06
-0.38%
Davis International Y

SRZN and

Correlation & Price change

A.I.dvisor tells us that SRZN and UPB have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SRZN and UPB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SRZN
1D Price
Change %
SRZN100%
+4.25%
UPB - SRZN
28%
Poorly correlated
-2.62%
KMSTF - SRZN
27%
Poorly correlated
N/A
CGEM - SRZN
27%
Poorly correlated
-1.05%
PDSB - SRZN
27%
Poorly correlated
-4.93%
DWTX - SRZN
27%
Poorly correlated
-2.93%
More

UPB and

Correlation & Price change

A.I.dvisor indicates that over the last year, UPB has been loosely correlated with ZBIO. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if UPB jumps, then ZBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To UPB
1D Price
Change %
UPB100%
-2.62%
ZBIO - UPB
41%
Loosely correlated
+2.60%
CRVS - UPB
41%
Loosely correlated
-1.98%
IPSC - UPB
40%
Loosely correlated
+4.82%
IDYA - UPB
40%
Loosely correlated
-1.72%
RXRX - UPB
40%
Loosely correlated
-3.12%
More